PMID- 30251403
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20211217
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Print)
IS  - 1524-6175 (Linking)
VI  - 20
IP  - 10
DP  - 2018 Oct
TI  - Hydrochlorothiazide vs chlorthalidone, indapamide, and 
      potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular 
      hypertrophy: A systematic review and meta-analysis.
PG  - 1507-1515
LID - 10.1111/jch.13386 [doi]
AB  - Left ventricular hypertrophy develops in 36%-41% of hypertensive patients and 
      independently predicts cardiovascular events and total mortality. Moreover, 
      drug-induced reduction in left ventricular mass (LVM) correlates with improved 
      prognosis. The optimal thiazide-type diuretic for reducing LVM is unknown. 
      Evidence regarding potency, cardiovascular events, sodium, and potassium 
      suggested the hypothesis that "CHIP" diuretics (CHlorthalidone, Indapamide, and 
      Potassium-sparing diuretic/hydrochlorothiazide [PSD/HCTZ]) would reduce LVM more 
      than HCTZ. Systematic searches of five databases were conducted. Among the 38 
      randomized trials, a 1% reduction in systolic blood pressure (SBP) predicted a 1% 
      reduction in LVM, P = 0.00001. CHIP-HCTZ differences in reducing LVM differed 
      across trials (ie, heterogeneity), making interpretation uncertain. However, 
      among the 28 double-blind trials, heterogeneity was undetectable, and HCTZ 
      reduced LVM (percent reduction [95% CI]) by -7.3 (-10.4, -4.2), P < 0.0001. CHIP 
      diuretics surpassed HCTZ in reducing LVM: chlorthalidone -8.2 (-14.7, -1.6), 
      P = 0.015; indapamide -7.5 (-12.7, -2.3), P = 0.005; and all CHIP diuretics 
      combined -7.7 (-12.2, -3.1), P < 0.001. The comparison of PSD/HCTZ with HCTZ had 
      low statistical power but favored PSD/HCTZ: -6.0 (-14.1, +2.1), P = 0.149. Thus, 
      compared to HCTZ, CHIP diuretics had twice the effect on LVM. CHIP diuretics did 
      not surpass HCTZ in reducing systolic or diastolic blood pressure: -0.3 (-5.0, 
      +4.3) and -1.6 (-5.6, +2.4), respectively. The strength of evidence that CHIP 
      diuretics surpass HCTZ for reducing LVM was high (GRADE criteria). In conclusion, 
      these novel results have demonstrated that CHIP diuretics reduce LVM 2-fold more 
      than HCTZ among hypertensive patients. Although generally related to LVM, blood 
      pressure fails to explain the superiority of CHIP diuretics for reducing LVM.
CI  - (c)2018 Wiley Periodicals, Inc.
FAU - Roush, George C
AU  - Roush GC
AUID- ORCID: 0000-0002-1822-813X
AD  - NYU School of Medicine, New York, New York.
FAU - Abdelfattah, Ramy
AU  - Abdelfattah R
AD  - NYU School of Medicine, New York, New York.
FAU - Song, Steven
AU  - Song S
AD  - SUNY Downstate Medical Center, New York, New York.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - University of Iowa Hospital and Clinics, Iowa City, Iowa.
FAU - Sica, Domenic A
AU  - Sica DA
AD  - Department of Medicine and Pharmacology, Virginia Commonwealth University, 
      Richmond, Virginia.
FAU - Kostis, John B
AU  - Kostis JB
AD  - Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New 
      Brunswick, New Jersey.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180924
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Diuretics, Potassium Sparing)
RN  - 0 (Sodium Chloride Symporter Inhibitors)
RN  - 0 (Thiazides)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - F089I0511L (Indapamide)
RN  - Q0MQD1073Q (Chlorthalidone)
SB  - IM
CIN - J Clin Hypertens (Greenwich). 2018 Oct;20(10):1516-1518. PMID: 30251479
CIN - J Clin Hypertens (Greenwich). 2019 Jan;21(1):141. PMID: 30461180
MH  - Antihypertensive Agents/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Chlorthalidone/administration & dosage/*pharmacology/therapeutic use
MH  - Diuretics, Potassium Sparing/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Humans
MH  - Hydrochlorothiazide/administration & dosage/*pharmacology/therapeutic use
MH  - Hypertension/complications/*drug therapy/physiopathology
MH  - Hypertrophy, Left Ventricular/*drug 
      therapy/epidemiology/physiopathology/prevention & control
MH  - Indapamide/administration & dosage/*pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Sodium Chloride Symporter Inhibitors/pharmacology
MH  - Thiazides/pharmacology/therapeutic use
PMC - PMC8030834
OTO - NOTNLM
OT  - chlorthalidone
OT  - diuretics, thiazide
OT  - hydrochlorothiazide
OT  - indapamide
OT  - left ventricular hypertrophy
OT  - potassium-sparing diuretic
COIS- None should be declared.
EDAT- 2018/09/27 06:00
MHDA- 2019/12/04 06:00
PMCR- 2018/09/24
CRDT- 2018/09/26 06:00
PHST- 2018/04/24 00:00 [received]
PHST- 2018/07/03 00:00 [revised]
PHST- 2018/07/13 00:00 [accepted]
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2018/09/26 06:00 [entrez]
PHST- 2018/09/24 00:00 [pmc-release]
AID - JCH13386 [pii]
AID - 10.1111/jch.13386 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2018 Oct;20(10):1507-1515. doi: 10.1111/jch.13386. 
      Epub 2018 Sep 24.